Anticoagulation and venous thromboembolism

Anticoagulants are a critical therapy to prevent and treat thromboembolic disorders. Bleeding remains a primary concern for patients prescribed anticoagulation medications — and treatment requires a careful balance between risks and benefits. COVID-19 adds an additional layer of complexity to anticoagulant dosing. EQIC’s anticoagulation and VTE programming focuses on education to ensure accurate prescription of prophylaxis and proper dose administration.

Assessments

Hospital tools

• VTE surveillance tool - EQIC
• Anticoagulation surveillance tool - EQIC
• RCIP VTE assessment - EQIC

Patient risk assessments

• Padua predictive score for VTE among hospitalized medical patients - NLM, NIH, HHS
• The international medical prevention registry on venous thromboembolism (IMPROVE-VTE) score - NLM, NIH, HHS
• IMPROVE-BLEED risk score - NLM, NIH, HHS
• Preventing hospital-associated venous thromboembolism - AHRQ

Toolkits and guidelines

Medical guidelines

• Advancing anticoagulation stewardship: A playbook – Anticoagulation Forum
• Sentinel event alert 61: Managing the risks of direct oral anticoagulants – The Joint Commission
• Clinical practice guidelines on VTE – American Society of Hematology
• Recommendations for VTE prophylaxis in medically ill patients – Annals of Vascular Disease
• Preventing hospital-associated venous thromboembolism - AHRQ

Prophylaxis for medical patients

• VTE prophylaxis in acutely ill medical patients – Anticoagulation Forum
• Order set: VTE prophylaxis for the medically ill patient - Anticoagulation Forum
• Recommendations for prophylaxis in medically ill patients based on risk scores – NLM, NIH, HHS

Surgical guidelines

• 2019 guidelines for management of venous thromboembolism: Prevention of venous thromboembolism in surgical hospitalized patients – American Society of Hematology